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Upon stimulation murine macrophages produce high levels of nitric oxide (NO), a potent microbicidal and tumoricidal
agent recently also implicated as a mediator of antiviral defense. As dysregulated production of NO may lead to extensive
tissue damage, the production of this powerful mediator is tightly regulated. Viral infection, however, may alter the regulation
of certain macrophage functions, and recent work from our group demonstrated that viral infection—via induction of
interferon-ab synthesis—may either prime for or down-modulate NO production. In light of antiviral activities of NO, down-
modulation of NO production in viral infection would seem contradictory to antiviral defense. As others, however, have
provided evidence that NO production may contribute to pathogenesis of infection with several neurotropic viruses, the
role of NO production was investigated in vitro and in vivo in murine macrophages and in BALB/c mice infected with tick-
borne encephalitis virus (TBE-V), a flavivirus. Macrophages from TBE-V-infected mice, but not from control mice, spontane-
ously produced NO upon culture in vitro. In contrast to the inhibitory effect of NO on replication of several poxviruses and
herpes simplex virus, high levels of NO production did not display an inhibitory influence on TBE-V replication in vitro. And
finally, in vivo administration of a competitive inhibitor of NO production, aminoguanidine, to TBE-V-infected mice significantly
increased their mean survival time. Our results thus demonstrate that the antiviral activity of NO in vitro may be confined
to certain viruses, whereas others remain unaffected. Furthermore, we provide evidence that NO production may even
contribute to pathogenesis of viral infection in vivo. q 1996 Academic Press, Inc.
Upon suitable stimulation many mammalian cells are infection with several neurotropic viruses (7–9), and
capable of de novo expressing inducible nitric oxide syn- consequently IFN-ab-mediated down-modulation of high-
thase (NOS), and once expressed this enzyme produces level nitric oxide production might well serve to avoid or
large amounts of nitric oxide (NO) for prolonged periods reduce tissue damage.
of time. While dysregulated high-level production of NO To gain further insight regarding the biological role
contributes to pathogenesis of a variety of diseases (1), of nitric oxide in viral infection—antiviral activity and/or
NO from this source also fulfills a plethora of physiologi- tissue damage—we investigated nitric oxide production
cal functions. For macrophages, in particular, NO is now in relation to experimental infection of mice with TBE-V.
established to be a key mediator of defense against bac- Antiviral activity of high levels of NO has so far been
teria, parasites, and tumor cells. More recently, high-level demonstrated for certain DNA viruses (2–5), and low-
NO production has also been demonstrated to play a level constitutive NO production by a neuronal cell line
role in antiviral defense, in particular against several was shown to inhibit replication of vesicular stomatitis
members of the Poxviridae family (2–4) and herpes sim- virus, an RNA virus of the Rhabdoviridae family (10). To
plex virus type 1 (2, 5). test a potential antiviral effect of NO on TBE-V, we used
We have lately demonstrated that interferon (IFN)-g a tissue culture system very similar to those used in
plus tumor necrosis factor-a-stimulated production of NO other studies (2). Peritoneal macrophages were prepared
was down-modulated in macrophages infected with tick- by adherence to plastic and were then cultured in the
borne encephalitis virus (TBE-V), a flavivirus, due to IFN- presence or absence of 300 mM aminoguanidine (AG), a
ab produced by virus-infected cells (6). Thus, virus-in- competitive inhibitor of enzymatic NO production. Subse-
duced IFN-ab would seem to antagonize production of quently, macrophages were infected with TBE-V at 5
an eventually antivirally active effector molecule, NO, and plaque-forming units (PFU) per cell, and after 5 hr nonad-
thereby seemingly counteract antiviral defense. Others, sorbed virus was removed. Macrophages were then
however, found NO to contribute to the pathogenesis of mock-treated or stimulated with LPS (Escherichia coli
0111:B4 LPS; Sigma Chemical Co., St. Louis, MO), IFN-
g (Boehringer Mannheim, Mannheim, FRG), or by priming1 To whom correspondence and reprint requests should be ad-
dressed. Fax: 0043-1-4081091-13. for 2 hr with IFN-g before addition of LPS as a triggering
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FIG. 1. (A) In vitro: NO production by and TBE-V replication in macrophages are not inversely related. Thioglycolate-induced, peritoneal exudate
macrophages were prepared by adherence of 2 1 105 peritoneal exudate cells per well of 96-well cluster plates for 2 hr before nonadherent cells
were removed by washing. Macrophages were then infected with TBE-V (5 hr with 5 plaque-forming units per cell), before nonadsorbed virus was
washed away. Macrophages were mock-treated or stimulated by addition of 10 U/ml IFN-g, 1 mg/ml LPS, or by priming for 2 hr with IFN-g and
subsequent triggering with LPS. After 72 hr, TBE-V production (left) was quantitated by plaque assay (11), and nitric oxide production (right) was
determined by Griess reaction as described (6). (B) In vivo: In vivo administration of AG, an inhibitor of NO production, increases MST of mice after
infection with TBE-V. Mice were infected by intraperitoneal injection of 1000 PFU TBE-V. Two hours earlier, and subsequently daily for 5 days, mice
were intravenously injected with 0.2 ml AG solutions in PBS as indicated. Significance of differences as compared to PBS-treated controls was
tested with Student’s t test: *P  0.001.
signal. NO production was determined after 72 hr by of IFN-g plus LPS was not any more inhibitory for
viral replication compared to IFN-g alone (left panel),Griess reaction as described (6), and progeny TBE-V was
tirated in a plaque assay on porcine stable cells (11). while TBE-V-infected macrophages produced massive
amounts of NO upon treatment with these stimuli (rightAs can be seen in Fig. 1A (hatched bars), unstimulated
panel). The presence of 300 mM AG (Fig. 1A, solid bars)control macrophages produce large amounts of TBE-V
completely abolished NO production (Fig. 1A, rightprogeny over the 72-hr observation period (left panel);
panel), whereas AG had no significant effect on TBE-Vhowever, they do not produce NO (right panel). When
replication. Thus, the reduced levels of TBE-V replicationTBE-V-infected macrophages were stimulated with LPS,
in IFN-g- or IFN-g plus LPS-treated macrophages werethey produced considerable amounts of NO (right panel)
caused by the IFN-g-induced antiviral state, and not bydue to priming by endogenously produced IFN-ab as
NO production. Consequently, these experiments dem-described earlier (6); however, viral replication remained
onstrate that in contrast to antiviral activity of NO in otherunchanged (left panel). IFN-g, as expected from its well-
viral systems, NO does not exert an inhibitory influenceestablished antiviral activity, massively reduced viral rep-
on replication of a flavivirus, TBE-V.lication (left panel) in TBE-V-infected macrophages, al-
though NO production was undetectable (right panel). This difference may have several reasons, but inhibi-
tion of enzymes with a role in DNA synthesis, like, forFinally, exposure of macrophages to the combination
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example, ribonucleotide reductase, was suggested to ex- the contribution of NO production may be in the patho-
genesis of TBE-V infection. In agreement with others (12)plain the NO-mediated block in DNA synthesis of vac-
cinia virus (3, 4), and this mechanism might function with who by spin trapping of NO and subsequent electron
paramagnetic resonance spectroscopy detected ele-the other poxviruses and herpes simplex virus type 1,
all DNA viruses, while leaving RNA viruses like TBE-V vated NO production in the brain of animals after infec-
tion with two neurotropic viruses (Borna disease virus,unaffected. While low-level constitutive NO production
by a neuronal cell line was recently shown to inhibit rabies virus), we would interpret the lack of detectable
elevation in systemically produced NO to argue for localreplication of vesicular stomatitis virus, an RNA virus of
the Rhabdoviridae family (10), the reasons for the ob- rather than systemic production of NO. One might hy-
pothesize that NO-mediated damage to the blood–brainserved differences currently have to remain open.
As we have demonstrated that TBE-V infection may barrier facilitating the access of TBE-V to its target organ
may be one of the possible mechanisms. Furthermore,prime for NO production in vitro (6), we were curious
to see whether modulation of NO production was also high amounts of immunologically induced NO may be
involved in brain tissue damage as suggested for infec-occurring in infection with TBE-V in vivo. Thus, peritoneal
macrophages were prepared from TBE-V-infected mice tion of the brain with lymphocytic choriomeningitis virus
(7) or Borna disease virus (8). We would like to empha-at different times after challenge, and NO production was
evaluated. And indeed, macrophages obtained 7 days size, however, that as administration of AG did not result
in improved survival of mice, but only in prolongation ofafter infection of mice with 1000 PFU TBE-V spontane-
ously produced NO in vitro, whereas NO remained unde- MST after TBE-V challenge, NO production may not be
crucial for disease development, but may rather contrib-tectable in cultures of control macrophages [nitrite (mM)
{ SEM after 72 hr culture in vitro: TBE-V infected, 11.2 ute to pathogenesis.
Taken together, our results suggest that NO, although{ 0.8; controls, 1.43 { 0.4]. Thus, peritoneal macro-
phages of mice at late stages of infection [Day 7 after being antivirally active for certain viruses, may fail to
function as an effector of antiviral defense and in otherinfection, mean survival time (MST)  9 days] have been
stimulated in vivo for NO production. viral infections, as shown for TBE-V, may even contribute
to disease development.Work by others has implicated that NO may contribute
to pathogenesis of infection with several neurotropic vi-
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